Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA, Atkins MB, et al. Systemic therapy for melanoma: ASCO guideline update. J Clin Oncol. 2023;41:4794–820. https://doi.org/10.1200/JCO.23.01136.
Google ScholarÂ
Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol. 2024;35:485–90. https://doi.org/10.1016/j.annonc.2024.03.001.
Google ScholarÂ
Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, et al. Non-small cell lung cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22:249–74. https://doi.org/10.6004/jnccn.2204.0023.
Google ScholarÂ
Barragan-Carrillo R, Scavuzzo A, Jimenez-Rios MA, Sobrevilla-Moreno N. Management of metastatic renal cell carcinoma: guideline updates. Eur Urol Focus. 2025;11:436–9. https://doi.org/10.1016/j.euf.2025.04.001.
Google ScholarÂ
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64. https://doi.org/10.1038/nrc3239.
Google ScholarÂ
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–5. https://doi.org/10.1126/science.aar4060.
Google ScholarÂ
Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131:58–67. https://doi.org/10.1182/blood-2017-06-741033.
Google ScholarÂ
Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48:434–52. https://doi.org/10.1016/j.immuni.2018.03.014.
Google ScholarÂ
Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807–21. https://doi.org/10.1038/s41423-020-0488-6.
Google ScholarÂ
Arrieta VA, Dmello C, McGrail DJ, Brat DJ, Lee-Chang C, Heimberger AB, et al. Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. J Clin Invest. 2023;133:e163447. https://doi.org/10.1172/JCI163447.
Google ScholarÂ
Nabet BY, Hamidi H, Lee MC, Banchereau R, Morris S, Adler L, et al. Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. Cancer Cell. 2024;42:429–443.e4. https://doi.org/10.1016/j.ccell.2024.01.010.
Google ScholarÂ
Yasuda T, Wang YA. Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development. Trends Cancer. 2024;10:627–42. https://doi.org/10.1016/j.trecan.2024.03.008.
Google ScholarÂ
Wang X, Yang Y, Su K, Zhao Z, Liu X, Xiong Q, et al. Immune circadian clock and tumorigenesis. Chin Sci Bull. 2025;70:3446–59. https://doi.org/10.1360/TB-2024-0874.
Google ScholarÂ
Lévi F. Circadian chronotherapy for human cancers. Lancet Oncol. 2001;2:307–15. https://doi.org/10.1016/S1470-2045(00)00326-0.
Google ScholarÂ
Sancar A, Van Gelder RN. Clocks, cancer, and chronochemotherapy. Science. 2021;371:eabb0738. https://doi.org/10.1126/science.abb0738.
Google ScholarÂ
Zhou L, Zhang Z, Nice E, Huang C, Zhang W, Tang Y. Circadian rhythms and cancers: The intrinsic links and therapeutic potentials. J Hematol Oncol. 2022;15:21. https://doi.org/10.1186/s13045-022-01238-y.
Google ScholarÂ
Eriguchi M, Levi F, Hisa T, Yanagie H, Nonaka Y, Takeda Y. Chronotherapy for cancer. Biomed Pharmacother. 2003;57:92s–95s. https://doi.org/10.1016/j.biopha.2003.08.012. Suppl 1.
Google ScholarÂ
Scheiermann C, Kunisaki Y, Frenette PS. Circadian control of the immune system. Nat Rev Immunol. 2013;13:190–8. https://doi.org/10.1038/nri3386.
Google ScholarÂ
Scheiermann C, Gibbs J, Ince L, Loudon A. Clocking in to immunity. Nat Rev Immunol. 2018;18:423–37. https://doi.org/10.1038/s41577-018-0008-4.
Google ScholarÂ
Damato AR, Herzog ED. Circadian clock synchrony and chronotherapy opportunities in cancer treatment. Semin Cell Dev Biol. 2022;126:27–36. https://doi.org/10.1016/j.semcdb.2021.07.017.
Google ScholarÂ
Ding J, Chen P, Qi C. Circadian rhythm regulation in the immune system. Immunology. 2024;171:525–33. https://doi.org/10.1111/imm.13747.
Google ScholarÂ
Landré T, Karaboué A, Buchwald ZS, Innominato PF, Qian DC, Assié JB, et al. Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis. ESMO Open. 2024;9:102220. https://doi.org/10.1016/j.esmoop.2023.102220.
Google ScholarÂ
Karaboué A, Innominato PF, Wreglesworth NI, Duchemann B, Adam R, Lévi FA. Why does circadian timing of administration matter for immune checkpoint inhibitors’ efficacy? Br J Cancer. 2024;131:783–96. https://doi.org/10.1038/s41416-024-02704-9.
Google ScholarÂ
Nagy S, Hussein A, Kesselman MM. The Importance of Timing in Immunotherapy: A Systematic Review. Cureus. 2025;17:e82994. https://doi.org/10.7759/cureus.82994.
Google ScholarÂ
Janse van Rensburg HJ, Liu Z, Abdul Razak AR, Spreafico A, Bedard PL, Hansen AR, et al. The effect of circadian rhythm on clinical outcome in patients receiving pembrolizumab in the INSPIRE pan-cancer trial. J Clin Oncol. 2022;40:2589. https://doi.org/10.1200/jco.2022.40.16_suppl.2589. (Suppl 16)(abstract).
Google ScholarÂ
Janopaul-Naylor JR, Boe L, Yu Y, Sherman EJ, Pfister DG, Lee NY, et al. Effect of time-of-day nivolumab and stereotactic body radiotherapy in metastatic head and neck squamous cell carcinoma: A secondary analysis of a prospective randomized trial. Head Neck. 2024;46:2292–2300. https://doi.org/10.1002/hed.27825.
Google ScholarÂ
Guo X, Qin L, Wang X, Geng Q, Li D, Lu Y, et al. Chronological effects of immune checkpoint inhibitors in non-small cell lung cancer. Immunology. 2025;174:402–10. https://doi.org/10.1111/imm.13897.
Google ScholarÂ
Bosetti T, Kennedy O, Califano R, Waddell T, Serra M, Metcalf R, et al. Overall survival according to timing of immune checkpoint inhibitors administration in patients with advanced cancer: Results from a large single-centre cohort analysis. J Clin Oncol. 2025;43:2662. https://doi.org/10.1200/JCO.2025.43.16_suppl.2662. (Suppl 16)(abstract).
Google ScholarÂ
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71.
Google ScholarÂ
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34. https://doi.org/10.1002/(sici)1097-0258(19981230)17:24. <2815::aid-sim110>3.0.co;2-8.
Google ScholarÂ
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https://doi.org/10.1136/bmj.i4919.
Google ScholarÂ
Qian DC, Kleber T, Brammer B, Xu KM, Switchenko JM, Janopaul-Naylor JR, et al. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study. Lancet Oncol. 2021;22:1777–86. https://doi.org/10.1016/S1470-2045(21)00546-5.
Google ScholarÂ
Cortellini A, Barrichello APC, Alessi JV, Ricciuti B, Vaz VR, Newsom-Davis T, et al. A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions. Ann Oncol. 2022;33:1202–4. https://doi.org/10.1016/j.annonc.2022.07.1851. (letter).
Google ScholarÂ
Karaboué A, Collon T, Pavese I, Bodiguel V, Cucherousset J, Zakine E, et al. Time-dependent efficacy of checkpoint inhibitor nivolumab: results from a pilot study in patients with metastatic non-small-cell lung cancer. Cancers. 2022;14:896. https://doi.org/10.3390/cancers14040896.
Google ScholarÂ
Dizman N, Govindarajan A, Zengin ZB, Meza L, Tripathi N, Sayegh N, et al. Association between time-of-day of immune checkpoint blockade administration and outcomes in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2023;21:530–6. https://doi.org/10.1016/j.clgc.2023.06.004.
Google ScholarÂ
Nomura M, Hosokai T, Tamaoki M, Yokoyama A, Matsumoto S, Muto M. Timing of the infusion of nivolumab for patients with recurrent or metastatic squamous cell carcinoma of the esophagus influences its efficacy. Esophagus. 2023;20:722–31. https://doi.org/10.1007/s10388-023-01006-y.
Google ScholarÂ
Rousseau A, Tagliamento M, Auclin E, Aldea M, Frelaut M, Levy A, et al. Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Eur J Cancer. 2023;182:107–14. https://doi.org/10.1016/j.ejca.2023.01.007.
Google ScholarÂ
Yeung C, Kartolo A, Tong J, Hopman W, Baetz T. Association of Circadian Timing of Initial Infusions of Immune Checkpoint Inhibitors with Survival in Advanced Melanoma. Immunotherapy. 2023;15:819–26. https://doi.org/10.2217/imt-2022-0139.
Google ScholarÂ
Catozzi S, Assaad S, Delrieu L, Favier B, Dumas E, Hamy A-S, et al. Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study. Eur J Cancer. 2024;199:113571. https://doi.org/10.1016/j.ejca.2024.113571.
Google ScholarÂ
Patel JS, Woo Y, Draper A, Jansen CS, Carlisle JW, Innominato PF, et al. Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis. J Immunother Cancer. 2024;12:e008011. https://doi.org/10.1136/jitc-2023-008011.
Google ScholarÂ
Ruiz-Torres DA, Naegele S, Podury A, Wirth L, Shalhout SZ, Faden DL. Immunotherapy time of infusion impacts survival in head and neck cancer: A propensity score matched analysis. Oral Oncol. 2024;151:106761. https://doi.org/10.1016/j.oraloncology.2024.106761.
Google ScholarÂ
Tanaka T, Suzuki H, Yamaguchi S, Shimotsuura Y, Nagasu S, Murotani K, et al. Efficacy of timing‑dependent infusion of nivolumab in patients with advanced gastric cancer. Oncol Lett. 2024;28:463. https://doi.org/10.3892/ol.2024.14596.
Google ScholarÂ
Zheng Y, Shi F, Sun L, Guo J, Ren T, Ma J. Effect of immune checkpoint inhibitor time-of-day infusion on survival in advanced biliary tract cancer: a propensity score-matched analysis. Front Immunol. 2024;15:1512972. https://doi.org/10.3389/fimmu.2024.1512972.
Google ScholarÂ
Amici M, Neveu E, Poizeau F, Edeline J, Lesimple T, Oger E, et al. The impact of the time-of-day in the administration of immunotherapy and its efficacy in patients with advanced melanoma: A retrospective observational study. Ann Dermatol Venereol. 2025;152:103371. https://doi.org/10.1016/j.annder.2025.103371.
Google ScholarÂ
Cheng C, Cheng X, Wang T. Overall survival according to time-of-day of combined immuno-chemotherapy for advanced gastric cancer: a propensity score-matched analysis. Front Immunol. 2025;16:1653218. https://doi.org/10.3389/fimmu.2025.1653218.
Google ScholarÂ
Ersoy M. Optimizing Nivolumab Efficacy: The Role of Dosing Time in Advanced Non-Small Cell Lung Cancer. Med Sci Monit. 2025;31:e950963. https://doi.org/10.12659/MSM.950963.
Google ScholarÂ
Furubayashi N, Mochida M, Kijima A, Fujimoto Y, Nakamura M, Negishi T. Outcomes of Avelumab Treatment in Advanced Urothelial Carcinoma According to Age, Performance Status, and Timing. Vivo. 2025;39:976–87. https://doi.org/10.21873/invivo.13903.
Google ScholarÂ
Gomez-Randulfe I, Pearce M, Netto D, Ward R, Califano R. Association between immunotherapy timing and efficacy in non-small cell lung cancer: a comprehensive analysis at a high-volume specialist centre. Transl Lung Cancer Res. 2025;14:72–80. https://doi.org/10.21037/tlcr-24-571.
Google ScholarÂ
Gonçalves L, Guedes H, Fortuna AR, Lemos T, Gramaça J, Mourão N, et al. Avelumab Maintenance Therapy in Advanced Urothelial Carcinoma: Implications of Timing and Treatment Sequencing. Cancers. 2025;17:898. https://doi.org/10.3390/cancers17050898.
Google ScholarÂ
Huang Z, Karaboué A, Zeng L, Lecoeuvre A, Zhang L, Li X-M, et al. Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental study. eBioMedicine. 2025;113:105607. https://doi.org/10.1016/j.ebiom.2025.105607.
Google ScholarÂ
Huang Z, Ruan Z, Xu S, Zou N, Deng L, Yan H, et al. Overall survival according to time-of-day of immunochemotherapy for extensive-stage small cell lung cancer. Cancer. 2025;131:e70126. https://doi.org/10.1002/cncr.70126.
Google ScholarÂ
Iwahashi Y, Tamiya A, Tanaka T, Tamiya M, Tsukaguchi A, Inagaki Y, et al. Association Between Administration Timing and Efficacy of Nivolumab in Non-small Cell Lung Cancer Treatment. Anticancer Res. 2025;45:5077–84. https://doi.org/10.21873/anticanres.17848.
Google ScholarÂ
Naganuma A, Kakizaki S, Hatanaka T, Hiraoka A, Tada T, Hirooka M, et al. Impact of time-of-day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study. Hepatol Res. 2025;55:741–51. https://doi.org/10.1111/hepr.14171.
Google ScholarÂ
Nepote A, Burghgraeve G, Pedrani M, Gomez Ramos AJ, Saporita I, Spataro V, et al. ChronoimmunoTOX: a single-institution retrospective study on how the time of administration impacts immune checkpoint inhibitor efficacy and toxicity in melanoma. J Clin Med. 2026;15:69. https://doi.org/10.3390/jcm15010069.
Google ScholarÂ
Tsukaguchi A, Matsumoto K, Tamiya A, Tamiya M, Mori M, Suzuki H, et al. Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: a retrospective multicenter study. Eur J Cancer. 2025;228:115748. https://doi.org/10.1016/j.ejca.2025.115748.
Google ScholarÂ
Van Loocke P, Beuselinck B, Meulemans J, Nuyts S, Willaert R, Di Santo D, et al. Impact of time-of-day administration of immune checkpoint inhibitors on survival outcomes in patients with recurrent/metastatic head and neck cancer (R/M HNSCC): a retrospective cohort study. Oral Oncol. 2025;171:107772. https://doi.org/10.1016/j.oraloncology.2025.107772.
Google ScholarÂ
Ishizuka Y, Narita Y, Sakakida T, Wakabayashi M, Kodama H, Honda K, et al. Impact of nivolumab monotherapy infusion time-of-day on short- and long-term outcomes in patients with metastatic gastric cancer. Ther Adv Med Oncol. 2025;17:17588359251339921. https://doi.org/10.1177/17588359251339921.
Google ScholarÂ
Vilalta A, Arasanz H, Rodriguez-Remirez M, Lopez I, Puyalto A, Lecumberri A, et al. 967P The time of anti-PD-1 infusion improves survival outcomes by fasting conditions simulation in non-small cell lung cancer. Ann Oncol. 2021;32:S835. https://doi.org/10.1016/j.annonc.2021.08.1352. (abstract).
Google ScholarÂ
Ortego I, Molina-Cerrillo J, Pinto A, Santoni M, Alonso-Gordoa T, Lopez Criado MP, et al. Time-of-day infusion of immunotherapy in metastatic urothelial cancer (mUC): Should it be considered to improve survival outcomes? J Clin Oncol. 2022;40:e16541. https://doi.org/10.1200/jco.2022.40.16_suppl.e16541. (abstract).
Google ScholarÂ
Fernandez-Mañas L, Gonzalez Aguado L, Aversa C, Ferrer-Mileo L, Garcia De Herreros M, Jiménez N, et al. Does the time-of-day administration of immune checkpoint inhibitors affect efficacy in patients with metastatic renal cell carcinoma? A single-center study. J Clin Oncol. 2023;41:681. https://doi.org/10.1200/jco.2023.41.6_suppl.681. (Suppl 6)(abstract).
Google ScholarÂ
Gomez-Randulfe Rodriguez MI, Pearce M, Gomes F, Lindsay C, Summers Y, Blackhall F, et al. 82 P the role of circadian rhythms in NSCLC immunotherapy efficacy: a focus on first dose timing. Immuno-Oncol Technol. 2023;20:100554. https://doi.org/10.1016/j.iotech.2023.100554. (abstract).
Google ScholarÂ
Karaboué A, Collon T, Innominato P, Chouahnia K, Adam R, Levi F. Improved survival on morning pembrolizumab with or without chemotherapy during initial treatment for stage IV non-small cell lung cancer. J Clin Oncol. 2023;41:e21055. https://doi.org/10.1200/jco.2023.41.16_suppl.e21055. (Suppl 16)(abstract).
Google ScholarÂ
Arroyave Ramirez AM, Motola D, Morales Garcia MG, Conde-Flores E. Impact of time-of-day administration of immunotherapy on overall survival among patients with metastatic renal cell carcinoma. J Clin Oncol. 2024;42:e16537. https://doi.org/10.1200/jco.2024.42.16_suppl.e16537. (Suppl 16)(abstract).
Google ScholarÂ
Gonçalves L, Goncalves D, Casanelles TE, Guerra LP, Menezes MB, Duarte Branco V, et al. Retro TIMing: a multicentric retrospective analysis of immunotherapy timing in metastatic melanoma. J Clin Oncol. 2024;42:9542. https://doi.org/10.1200/jco.2024.42.16_suppl.9542. (Suppl 16)(abstract).
Google ScholarÂ
Pascale A, Allard MA, Benamar A, Levi F, Adam R, Rosmorduc O. Prognostic value of the timing of immune checkpoint inhibitors infusion in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2024;42:457. https://doi.org/10.1200/jco.2024.42.3_suppl.457. (Suppl 3)(abstract).
Google ScholarÂ
Tagawa R, Takemoto S, Gyotoku H, Taniguchi H, Matsuo M, Tomono H, et al. EP.11A.16 infusion timing of ICI monotherapy in patients with advanced NSCLC: a single institution-retrospective study. J Thorac Oncol. 2024;19:S602–S603. https://doi.org/10.1016/j.jtho.2024.09.1127. (abstract).
Google ScholarÂ
Tsunoki T, Kadowaki S, Mizuno T, Ishizuka Y, Sakakida T, Narita Y, et al. 413MO Impacts of time-of-day of nivolumab infusion on treatment efficacy for patients with head and neck squamous cell carcinoma. Ann Oncol. 2024;35:S1558. https://doi.org/10.1016/j.annonc.2024.10.436. (abstract).
Google ScholarÂ
Oya Y. MO47-1 Early administration of immune checkpoint inhibitors ± chemotherapy affects efficacy in patients with advanced NSCLC. Ann Oncol. 2025;36:S1712. https://doi.org/10.1016/j.annonc.2025.08.229. (abstract).
Google ScholarÂ
Schultz S, Mohr R, Knott A, Amundson B, King E, Chittavong V, et al. 159P Impact of initial timing of immune checkpoint inhibitor administration on outcomes in metastatic non-small cell lung cancer. Immuno-Oncol Technol. 2025;28:101242. https://doi.org/10.1016/j.iotech.2025.101242. (abstract).
Google ScholarÂ
Peters S, Dafni U, Federer-Gsponer J, Ballinger M, Christopeit M, Dimopoulou G, et al. LBA2 ETOP-Roche i-TIMES: Immunotherapy timing investigation on lung cancer survival. ESMO Open. 2026;11:106958. https://doi.org/10.1016/j.esmoop.2026.106958. (abstract).
Google ScholarÂ
Barrios CH, Montella TC, Ferreira CGM, De Marchi P, Coutinho LF, Lemos Duarte I, et al. Time-of-day infusion of immunotherapy may impact outcomes in advanced non-small cell lung cancer patients (NSCLC). J Clin Oncol. 2022;40:e21126. https://doi.org/10.1200/jco.2022.40.16_suppl.e21126.
Google ScholarÂ
Molina-Cerrillo J, Ortego I, Pinto A, Alonso-Gordoa T, Massari F, Aurilio G, et al. Does timing of immune checkpoint inhibitors (ICIs) administration in first line metastatic renal cell carcinoma (mRCC) have impact in survival outcomes? J Clin Oncol. 2022;40:e16512. https://doi.org/10.1200/jco.2022.40.16_suppl.e16512. (Suppl 16)(abstract).
Google ScholarÂ
Fey RM, Billo A, Clister T, Doan KL, Berry EG, Tibbitts DC, et al. Personalization of cancer treatment: exploring the role of chronotherapy in immune checkpoint inhibitor efficacy. Cancers. 2025;17:732. https://doi.org/10.3390/cancers17050732.
Google ScholarÂ
Chaudhari PB. Nivolumab–pearls of evidence. Indian J Med Paediatr Oncol. 2017;38:520–5. https://doi.org/10.4103/ijmpo.ijmpo_193_16.
Google ScholarÂ
Druzd D, Matveeva O, Ince L, Harrison U, He W, Schmal C, et al. Lymphocyte circadian clocks control lymph node trafficking and adaptive immune responses. Immunity. 2017;46:120–32. https://doi.org/10.1016/j.immuni.2016.12.011.
Google ScholarÂ
Xuan W, Khan F, James CD, Heimberger AB, Lesniak MS, Chen P. Circadian regulation of cancer cell and tumor microenvironment crosstalk. Trends Cell Biol. 2021;31:940–50. https://doi.org/10.1016/j.tcb.2021.06.008.
Google ScholarÂ
Wang C, Barnoud C, Cenerenti M, Sun M, Caffa I, Kizil B, et al. Dendritic cells direct circadian anti-tumour immune responses. Nature. 2023;614:136–43. https://doi.org/10.1038/s41586-022-05605-0.
Google ScholarÂ
Tsuruta A, Shiiba Y, Matsunaga N, Fujimoto M, Yoshida Y, Koyanagi S, et al. Diurnal expression of PD-1 on tumor-associated macrophages underlies the dosing time-dependent antitumor effects of the PD-1/PD-L1 inhibitor BMS-1 in B16/BL6 melanoma-bearing mice. Mol Cancer Res. 2022;20:972–82. https://doi.org/10.1158/1541-7786.MCR-21-0786.
Google ScholarÂ
Fortin BM, Pfeiffer SM, Insua-RodrÃguez J, Alshetaiwi H, Moshensky A, Song WA, et al. Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade. Nat Immunol. 2024;25:1257–69. https://doi.org/10.1038/s41590-024-01859-0.
Google ScholarÂ
Voigt RM, Forsyth CB, Green SJ, Engen PA, Keshavarzian A. Circadian rhythm and the gut microbiome. Int Rev Neurobiol. 2016;131:193–205. https://doi.org/10.1016/bs.irn.2016.07.002.
Google ScholarÂ
Nomura M, Nagatomo R, Doi K, Shimizu J, Baba K, Saito T, et al. Association of short-chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors. JAMA Netw Open. 2020;3:e202895. https://doi.org/10.1001/jamanetworkopen.2020.2895.
Google ScholarÂ
Centanni M, Moes DJAR, Trocóniz IF, Ciccolini J, van Hasselt JGC. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet. 2019;58:835–57. https://doi.org/10.1007/s40262-019-00748-2.
Google ScholarÂ
Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. Annu Rev Pharm Toxicol. 2010;50:377–421. https://doi.org/10.1146/annurev.pharmtox.48.113006.094626.
Google ScholarÂ
Spiegel D, Giese-Davis J. Depression and cancer: Mechanisms and disease progression. Biol Psychiatry. 2003;54:269–82. https://doi.org/10.1016/s0006-3223(03)00566-3.
Google ScholarÂ
Cavadini G, Petrzilka S, Kohler P, Jud C, Tobler I, Birchler T, et al. TNF-alpha suppresses the expression of clock genes by interfering with E-box-mediated transcription. Proc Natl Acad Sci USA. 2007;104:12843–8. https://doi.org/10.1073/pnas.0701466104.
Google ScholarÂ
Sulli G, Lam MTY, Panda S. Interplay between circadian clock and cancer: New frontiers for cancer treatment. Trends Cancer. 2019;5:475–94. https://doi.org/10.1016/j.trecan.2019.07.002.
Google ScholarÂ
Mormont MC, Waterhouse J, Bleuzen P, Giacchetti S, Jami A, Bogdan A, et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 2000;6:3038–45.
Google ScholarÂ
Lévi FA, Okyar A, Hadadi E, Innominato PF, Ballesta A. Circadian regulation of drug responses: toward sex-specific and personalized chronotherapy. Annu Rev Pharm Toxicol. 2024;64:89–114. https://doi.org/10.1146/annurev-pharmtox-051920-095416.
Google ScholarÂ
Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17:233–47. https://doi.org/10.1038/nri.2017.1.
Google ScholarÂ
Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626–38. https://doi.org/10.1038/nri.2016.90.
Google ScholarÂ
Lewy AJ, Cutler NL, Sack RL. The endogenous melatonin profile as a marker for circadian phase position. J Biol Rhythms. 1999;14:227–36. https://doi.org/10.1177/074873099129000641.
Google ScholarÂ
Klerman EB, Brager A, Carskadon MA, Depner CM, Foster R, Goel N, et al. Keeping an eye on circadian time in clinical research and medicine. Clin Transl Med. 2022;12:e1131. https://doi.org/10.1002/ctm2.1131.
Google ScholarÂ
Wittenbrink N, Ananthasubramaniam B, Münch M, Koller B, Maier B, Weschke C, et al. High-accuracy determination of internal circadian time from a single blood sample. J Clin Invest. 2018;128:3826–39. https://doi.org/10.1172/JCI120874.
Google ScholarÂ
Depner CM, Cheng PC, Devine JK, Khosla S, de Zambotti M, Robillard R, et al. Wearable technologies for developing sleep and circadian biomarkers: A summary of workshop discussions. Sleep. 2020;43:zsz254. https://doi.org/10.1093/sleep/zsz254.
Google ScholarÂ
Duffy JF, Czeisler CA. Effect of light on human circadian physiology. Sleep Med Clin. 2009;4:165–77. https://doi.org/10.1016/j.jsmc.2009.01.004.
Google ScholarÂ
Ribas-Latre A, Fernández-Veledo S, Vendrell J. Time-restricted eating, the clock ticking behind the scenes. Front Pharm. 2024;15:1428601. https://doi.org/10.3389/fphar.2024.1428601.
Google ScholarÂ
Ogunlusi O, Ghosh A, Sarkar M, Carter K, Davuluri H, Chakraborty M, et al. Rhythm is essential: unraveling the relation between the circadian clock and cancer. Crit Rev Oncol Hematol. 2025;208:104632. https://doi.org/10.1016/j.critrevonc.2025.104632.
Google ScholarÂ
Huang Z, Zeng L, Ruan Z, Zeng Q, Yan H, Jiang W, et al. Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial. Nat Med. 2026;32:1233–40. https://doi.org/10.1038/s41591-025-04181-w.
Google ScholarÂ
